01/20/2026

A Fast-Acting Dupixent? Dr. Barry Quart, CEO, Connect Biopharma

01/13/2026

Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications

10/08/2025

Patients with high FeNO, eosinophil counts have greatest improvements with rademikibart

08/26/2025

Bengals have to start FAST with Ickey Woods. Interview with Ickey Woods and Barry Quart (start time: 00:24:00)

08/15/2025

Ickey Woods Foundation 2nd Annual Ickey's Bowling Shuffle Interview

08/15/2025

Ickey Woods and Connect Biopharma team up to tackle acute asthma attacks

08/14/2025

Connect Biopharma Partners with NFL Legend Ickey Woods and the Javonte Woods Foundation to Improve Asthma Education

08/14/2025

Connect Biopharma joins NFL star Ickey Woods for asthma education blitz

06/23/2025

FDA Trials And Tribulations With Connect Biopharma's Barry Quart

06/18/2025

A Biologic Designed to Treat Acute Exacerbations of Asthma and COPD

06/17/2025

Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma

06/10/2025

Transforming Care for COPD: Q&A with Barry Quart

06/06/2025

Next Generation Monoclonal Antibodies for Inflammatory Respiratory Diseases with Barry Quart Connect Biopharma

05/21/2025

Q&A with Barry Quart, CEO at Connect Biopharma

05/19/2025

Lung function improves for patients with asthma within 24 hours with rademikibart

05/15/2025

Connect Biopharma Initiates Phase 2 Seabreeze STAT Study To Test Rademikibart For Treating Acute COPD Exacerbations

05/14/2025

Connect Biopharma Announces New Phase 2 Study To Test Rademikibart For Acute Asthma Exacerbations

05/14/2025

Connect Biopharma begins Phase II trial of drug for acute exacerbations in asthma

04/09/2025

Rademikibart promise for uncontrolled asthma

04/02/2025

Rademikibart Yields Rapid Improvements in Moderate to Severe Uncontrolled Asthma

03/20/2025

Connect Bio Eyeing Commercial Partner for Inflammatory Disease Treatment